<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ibrexafungerp: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ibrexafungerp: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ibrexafungerp: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="131776" href="/d/html/131776.html" rel="external">see "Ibrexafungerp: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="131815" href="/d/html/131815.html" rel="external">see "Ibrexafungerp: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57580519"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of embryo-fetal toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Ibrexafungerp is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies.</p>
<p style="text-indent:0em;">For females of reproductive potential, verify that the patient is not pregnant prior to initiating ibrexafungerp treatment. Reassessing pregnancy status prior to each dose is recommended when ibrexafungerp is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).</p>
<p style="text-indent:0em;">Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis and throughout the 6-month treatment period for reduction in the incidence of RVVC with ibrexafungerp and for 4 days after the last dose.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55942235"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Brexafemme</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55832919"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Oral;</li>
<li>
                        Antifungal Agent, Triterpenoid</li></ul></div>
<div class="block doa drugH1Div" id="F55852023"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0438c731-a168-44a4-b672-4e1b74af8c34">Candidiasis, vulvovaginal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, vulvovaginal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute infection, treatment (alternative agent): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For mild/moderate infection in immunocompetent patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.1'])">Ref</a></span>); some experts also use for patients with severe infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36255448','lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36255448','lexi-content-ref-Sobel.1'])">Ref</a></span>). Reserve for those who cannot take fluconazole or have infection that is refractory or resistant to fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 300 mg every 12 hours for 1 day (2 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34467969','lexi-content-ref-34676663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34467969','lexi-content-ref-34676663'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent infection, reduction in incidence:</i>
<b>Oral: </b>300 mg every 12 hours for 1 day (2 doses); repeat monthly for a total of 6 months. <b>Note:</b> In clinical trials, participants had experienced ≥3 episodes in the previous year and received fluconazole for symptomatic treatment of their recurrent episode prior to initiating ibrexafungerp for reducing incidence of recurrent infection.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55852025"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F55852026"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh classes A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F55852024"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F55852191"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="131776" href="/d/html/131776.html" rel="external">see "Ibrexafungerp: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0438c731-a168-44a4-b672-4e1b74af8c34">Candidiasis, vulvovaginal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, vulvovaginal: </b>Postmenarchal Children and Adolescents: Oral: 300 mg every 12 hours for 2 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d42ff71-0878-4b80-b871-dc69c0dc2eb6">Candidiasis, vulvovaginal, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, vulvovaginal, recurrent (reduction in incidence):</b> Postmenarchal Children and Adolescents: Oral: 300 mg every 12 hours for 1 day (2 doses); repeat monthly for 6 months. <b>Note:</b> In clinical trials, participants had experienced ≥3 episodes in the previous year and received fluconazole treatment for symptomatic treatment of their recurrent episode prior to initiating ibrexafungerp.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F55852192"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F55852193"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Postmenarchal Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh classes A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F55836165"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10% to 11%), diarrhea (8% to 17%), nausea (5% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (&lt;2%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (&lt;2%), urinary tract infection (4%), vaginal hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&lt;2%)</p></div>
<div class="block coi drugH1Div" id="F55832922"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ibrexafungerp or any component of the formulation; pregnancy.</p></div>
<div class="block foc drugH1Div" id="F55942236"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brexafemme: 150 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye)]</p></div>
<div class="block geq drugH1Div" id="F55942234"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55989142"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Brexafemme Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $163.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F55852027"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Administer doses ~12 hours apart (eg, in the morning and in the evening).</p></div>
<div class="block admp drugH1Div" id="F55852194"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food; doses should be separated by ~12 hours.</p></div>
<div class="block meg drugH1Div" id="F57633031"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F214900s002lbl.pdf%23page%3D18&amp;token=iv3xw88mBVkYvnNhWzzelXXglLdLmxcQgSEoVmvKY6KMoRL5O6BJt2X%2F16t4ChN9vPbLQIf5oR8lXnMdQz1aJu8ieuB26pbtUvTx1vfzpYnbDtzY5Qi3xck5hi8o%2FJEd&amp;TOPIC_ID=131762" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214900s002lbl.pdf#page=18</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F55832921"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Candidiasis, vulvovaginal:</b> Treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC in adult and postmenarchal pediatric patients.</p></div>
<div class="block mst drugH1Div" id="F56381753"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55868972"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F55868969"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ibrexafungerp.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ibrexafungerp.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ibrexafungerp. Management: Decrease the ibrexafungerp dose to 150 mg every 12 hours for 2 doses in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55852008"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation and also reassess prior to each monthly dose when used for recurrent vulvovaginal candidiasis (VVC).</p>
<p style="text-indent:0em;margin-top:2em;">When used for the single-day treatment of VVC, patients who may become pregnant should use effective contraception during therapy and for 4 days after the last ibrexafungerp dose. When used for recurrent VVC, effective contraception should be used throughout the 6-month treatment period and for 4 days after the last dose of ibrexafungerp.</p></div>
<div class="block pri drugH1Div" id="F55852009"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to ibrexafungerp may cause fetal harm. Use during pregnancy is contraindicated.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ibrexafungerp is ongoing. Health care providers are encouraged to enroll patients exposed to ibrexafungerp during pregnancy in the Pregnancy Registry (1-888-982-7299). Patients whose pregnancy is detected within 4 days after exposure should also be enrolled.</p></div>
<div class="block brc drugH1Div" id="F55852010"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ibrexafungerp is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F55852029"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pregnancy testing prior to initiating treatment; reassess pregnancy status prior to each dose when used monthly for reduction in incidence of recurrent vulvovaginal candidiasis.</p></div>
<div class="block pha drugH1Div" id="F55852014"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ibrexafungerp is a triterpenoid antifungal that inhibits glucan synthase, an enzyme involved in the formation of an essential component of the fungal cell wall (1,3-beta-D-glucan).</p></div>
<div class="block phk drugH1Div" id="F55852015"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Administration with a high-fat meal (800 to 1,000 calories; 50% fat) increased C<sub>max</sub> by 32% and AUC by 38%, compared to fasting.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~600 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%, primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydroxylation by CYP3A4, followed by glucuronidation and sulfation of a hydroxylated inactive metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~20 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 90% (51% as unchanged drug); Urine: 1%.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32746636">
<a name="32746636"></a>Azie N, Angulo D, Dehn B, Sobel JD. Oral ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. <i>Expert Opin Investig Drugs</i>. 2020;29(9):893-900. doi:10.1080/13543784.2020.1791820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrexafungerp-drug-information/abstract-text/32746636/pubmed" id="32746636" target="_blank">32746636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Brexafemme (ibrexafungerp) [prescribing information]. Jersey City, NJ: Scynexis Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36255448">
<a name="36255448"></a>Goje O, Sobel R, Nyirjesy P, et al. Oral ibrexafungerp for vulvovaginal candidiasis treatment: an analysis of VANISH 303 and VANISH 306. <i>J Womens Health (Larchmt)</i>. 2023;32(2):178-186. doi:10.1089/jwh.2022.0132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrexafungerp-drug-information/abstract-text/36255448/pubmed" id="36255448" target="_blank">36255448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34467969">
<a name="34467969"></a>Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303). <i>Clin Infect Dis</i>. 2022;74(11):1979-1985. doi:10.1093/cid/ciab750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrexafungerp-drug-information/abstract-text/34467969/pubmed" id="34467969" target="_blank">34467969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.1">
<a name="Sobel.1"></a>Sobel JD. Candida vulvovaginitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 9, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34676663">
<a name="34676663"></a>Sobel R, Nyirjesy P, Ghannoum MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). <i>BJOG</i>. 2022b;129(3):412-420. doi:10.1111/1471-0528.16972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrexafungerp-drug-information/abstract-text/34676663/pubmed" id="34676663" target="_blank">34676663</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131762 Version 57.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
